Antti Rannikko
Helsingin yliopisto
H-index: 40
Europe-Finland
Top articles of Antti Rannikko
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures. | Stephen J Freedland John Mulhall Martin Gleave Ugo De Giorgi Fred Saad | 2024/2/1 | |
FAP/αSMA association with tumor visibility and progression in prostate cancer | Cancer Research | Jenni Säilä Timo-Pekka Lehto Annabrita Schoonenberg Katja Välimäki Andrew Erickson | 2024/3/22 |
MRI-targeted prostate biopsy introduces grade inflation and overtreatment | medRxiv | Abderrahim Oussama Batouche Eugen Czeizler Timo-Pekka Lehto Andrew Erickson Tolou Shadbahr | 2024/1/10 |
LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC … | Urologic Oncology: Seminars and Original Investigations | Stephen J Freedland Martin Gleave Ugo De Giorgi Antti Rannikko Christopher M Pieczonka | 2024/3/1 |
Protease-activated CDCP1 as a marker for aggressive primary prostate cancer and castration resistance | Cancer Research | Ruusu-Maaria Merivirta Timo-Pekka Lehto Antti Rannikko Tuomas Mirtti Hannu Koistinen | 2024/3/22 |
Using unsupervised topic modeling to uncover document hierarchy and latent topics in prostate cancer clinical texts | medRxiv | Tuulia Denti Wei Sun Shaoxiong Ji Hans Moen Oleg Kerro | 2024 |
Histomic and transcriptomic features of MRI‐visible and invisible clinically significant prostate cancers are associated with prognosis | International Journal of Cancer | Timo‐Pekka K Lehto Juho Pylväläinen Kevin Sandeman Anu Kenttämies Stig Nordling | 2024/3/1 |
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged≥ 75 years with non‐metastatic high‐risk prostate cancer … | BJU international | Sven Löffeler Helena Bertilsson Christoph Müller Kirsti Aas Hege Sagstuen Haugnes | 2024/3/12 |
Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial | JAMA | Anssi Auvinen Teuvo LJ Tammela Tuomas Mirtti Hans Lilja Teemu Tolonen | 2024/4/6 |
Early detection of clinically significant prostate cancer: protocol summary and statistical analysis plan for the ProScreen randomised trial | Kathryn R Nightingale Duke University Durham United States | 2017/10/1 | |
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS | The Oncologist | Neal D Shore Christian Gratzke Susan Feyerabend Patrick Werbrouck Joan Carles | 2024/2/23 |
FINPRO–a nationwide registry study on localized prostate cancer in Finland | European Urology | T Murtola T Hakkarainen M Lahelma P Pennanen M Pietilä | 2024/3/1 |
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study | World Journal of Urology | Ronja Hietikko Tuomas Mirtti Tuomas P Kilpeläinen Teemu Tolonen Anne Räisänen-Sokolowski | 2024/4/6 |
Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—a Comparison with the General Population | Cancer Epidemiology, Biomarkers & Prevention | Juho Pylväläinen Jaakko Hoffström Anu Kenttämies Anssi Auvinen Tuomas Mirtti | 2024/2/14 |
PI-RADS score 5 is a strong predictor for rapid prostate cancer specific death | European Urology | T Shadbahr J Pylväläinen J Hoffström A Kenttämies T Mirtti | 2024/3/1 |
PRECISE Version 2: Updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer | European Urology | Cameron Englman Davide Maffei Clare Allen Alex Kirkham Peter Albertsen | 2024/3/30 |
Negative MRI rules out clinically significant prostate cancer regardless of PI-RADS era | European Urology | T Shadbahr J Pylväläinen J Hoffström A Kenttämies T Mirtti | 2024/3/1 |
Protocol summary and statistical analysis plan for the randomized trial of early detection of clinically significant prostate cancer (ProScreen) | Critical Care and Resuscitation | Laurent Billot Brian Cuthbertson Anthony Gordon Farah Al-Beidh Maryam Correa | 2021/6/1 |
Cancer associated PSA-glycoforms as prostate cancer markers | Cancer Research | Hannu Koistinen Ruusu-Maaria Kovanen Timo-Pekka Lehto Antti Rannikko Tuomas Mirtti | 2023/4/4 |
The roles of proteases in prostate cancer | Hannu Koistinen Ruusu‐Maaria Kovanen Morley D Hollenberg Antoine Dufour Evette S Radisky | 2023/6 |
Co-Authors
